Olux E is owned by Mylan.
Olux E contains Clobetasol Propionate.
Olux E has a total of 2 drug patents out of which 0 drug patents have expired.
Olux E was authorised for market use on 12 January, 2007.
Olux E is available in aerosol, foam;topical dosage forms.
Olux E can be used as treatment of corticosteroid-responsive dermatoses.
The generics of Olux E are possible to be released after 05 November, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8962000||MYLAN||Microemulsion and sub-micron emulsion process and compositions|| |
(2 years from now)
|US8460641||MYLAN||Microemulsion process and composition|| |
(5 years from now)
Market Authorisation Date: 12 January, 2007
Treatment: Treatment of corticosteroid-responsive dermatoses
Dosage: AEROSOL, FOAM;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic